Share：
Share this content in WeChat
X
[Chinese][PDF]132679
• Original Article •
Study of Gd-EOB-DTPA T1 mapping in quantitatively staging hepatic fibrosis in a rabbit model
ZHU Zuhui  XING Wei  LIU Haifeng  WANG Qing  DU Ya’nan  LI Yufeng  ZHANG Jilei 

Cite this article as: Zhu ZH, Xing W, Liu HF, et al. Study of Gd-EOB-DTPA T1 mapping in quantitatively staging hepatic fibrosis in a rabbit model. Chin J Magn Reson Imaging, 2020, 11(10): 890-895. DOI:10.12015/issn.1674-8034.2020.10.011.


[Abstract] Objective: To explore parameters obtained by Gd-EOB-DTPA T1 mapping and extracellular volume fraction in evaluating hepatic fibrosis (HF) in a rabbit model.Materials and Methods: One hundred rabbits were randomly divided into two groups: the HF group (n=80) and the control group (n=20). The HF model was established by carbon tetrachloride (CCl4) in our experiments, whereas control rabbits received a subcutaneous injection of normal saline. After completing T1 mapping imaging, rabbits underwent pathological examination to determine the HF stage using the metavir classification system. Then, quantitative parameters including T1native, T110 min, T120 min, ECV10 min and ECV20 min were measured and compared among the different HF stages using spearman correlation coefficients and receiver operating characteristic curve.Results: In all, 14, 19, 15, 19, 18 rabbits had stage F0, F1, F2, F3 and F4, respectively, were included in this study. T1native (r=0.685), T110 min (r=0.428), T120 min (r=0.818), ECV10 min (r=0.278), and ECV20 min (r=0.766), increased with HF stage progression (P<0.001). The AUC of T120 min was higher than that of other quantitative parameters, with an AUC of 0.90, 0.93, 0.93 and 0.92 for staging≥F1, ≥F2, ≥F3, ≥F4, respectively.Conclusions: T1 mapping parameters and ECV fraction are closely associated with HF progression, indicating that this may be a promising method for quantitatively differentiating HF.
[Keywords] hepatic fibrosis；Gd-EOB-DTPA；T1 mapping；extracellular volume fraction；rabbit；animal experiment

ZHU Zuhui Department of Radiology, third Affiliated Hospital of Soochow University & Changzhou First People's Hospital, Changzhou 213003, China

XING Wei* Department of Radiology, third Affiliated Hospital of Soochow University & Changzhou First People's Hospital, Changzhou 213003, China

LIU Haifeng Department of Radiology, third Affiliated Hospital of Soochow University & Changzhou First People's Hospital, Changzhou 213003, China; Department of Radiology, Changzhou First People's Hospital, Lanzhou 730000, China

WANG Qing Department of Radiology, third Affiliated Hospital of Soochow University & Changzhou First People's Hospital, Changzhou 213003, China

DU Ya’nan Department of Radiology, third Affiliated Hospital of Soochow University & Changzhou First People's Hospital, Changzhou 213003, China

LI Yufeng Department of Radiology, third Affiliated Hospital of Soochow University & Changzhou First People's Hospital, Changzhou 213003, China

ZHANG Jilei Philips Healthcare, Shanghai 200072, China

*Correspondence to: Xing W, E-mail: suzhxingwei@suda.edu.cn

Conflicts of interest   None.

ACKNOWLEDGMENTS  This work was part of National Natural Science Foundation of China No. 81771798 Special Fund for Fundamental Scientific Research Business Expenses of Central Universities of Lanzhou University No. lzujbky-2019-cd04
Received  2020-05-27
Accepted  2020-06-30
DOI: 10.12015/issn.1674-8034.2020.10.011
Cite this article as: Zhu ZH, Xing W, Liu HF, et al. Study of Gd-EOB-DTPA T1 mapping in quantitatively staging hepatic fibrosis in a rabbit model. Chin J Magn Reson Imaging, 2020, 11(10): 890-895. DOI:10.12015/issn.1674-8034.2020.10.011.

[1]
Parola M, Pinzani M. Liver fibrosis: Pathophysiology, pathogenetic targets and clinical issues. Molecular Aspect Med, 2019, 65(2): 37-55.
[2]
Lemmer A, VanWagner LB. Assessment of advanced liver fibrosis and the risk for hepatic decompensation in patients with congestive hepatopathy. Hepatology, 2018, 68(4): 1633-1641.
[3]
Schuppan D, Ashfaq-Khan M, Yang AT, et al. Liver fibrosis: Direct antifibrotic agents and targeted therapies. Matrix Biol, 2018, 68-69(SI): 435-451.
[4]
Tacke F, Weiskirchen R. An update on the recent advances in antifibrotic therapy. Expert Rev Gastroenterol Hepatol, 2018, 12(11): 1143-1152.
[5]
Czeczok TW, Van Arnam JS, Wood LD, et al. The almost-normal liver biopsy: presentation, clinical associations, and outcome. Am J Surg Pathol, 2017, 41(9): 1247-1253.
[6]
Ning J, Yang Z, Xie S, et al. Hepatic function imaging using dynamic Gd-EOB-DTPA enhanced MRI and pharmacokinetic modeling. Magn Reson Med, 2017, 78(4): 1488-1495.
[7]
Heidenreich JF, Weng AM, Donhauser J, et al. T1- and ECV-mapping in clinical routine at 3 T: differences between MOLLI, ShMOLLI and SASHA. BMC Med Imaging, 2019, 19(1): 59.
[8]
Piechnik SK, Neubauer S, Ferreira VM. State-of-the-art review: stress T1 mapping-technical considerations, pitfalls and emerging clinical applications. MAGMA, 2018, 31(1): 131-141.
[9]
Ippolito D, Pecorelli A. Assessing liver function: diagnostic efficacy of parenchymal enhancement and liver volume ratio of Gd-EOB-DTPA-enhanced MRI study during interstitial and hepatobiliary phase. Abdom Radiol (NY), 2019, 44(4): 1340-1349.
[10]
吕倩，周锐志，李颖端,等. Gd-EOB-DTPA增强磁共振信号强度评价肝功能的价值研究.磁共振成像, 2019, 10(10): 752-756.
[11]
张学琴，陆健，张涛,等. Gd-EOB-DTPA增强T1 mapping成像对肝功能的评估价值.临床放射学杂志, 2018, 37(4): 652-655.
[12]
Xu M, Wang X, Zou Y, et al. Key role of liver sinusoidal endothelial cells in liver fibrosis. Biosci Trends, 2017, 11(2): 163-168.
[13]
Sciarra A, Schmidt S, Pellegrinelli A, et al. OATPB1/B3 and MRP3 expression in hepatocellular adenoma predicts Gd-EOB-DTPA uptake and correlates with risk of malignancy. Liver Int, 2019, 39(1): 158-167.
[14]
Zhou ZP, Long LL, Qiu WJ, et al. Comparison of 10- and 20-min hepatobiliary phase images on Gd-EOB-DTPA-enhanced MRI T1 mapping for liver function assessment in clinic. Abdom Radiol, 2017, 42(9): 2272-2278.
[15]
Sheng RF, Wang HQ, Yang L, et al. Assessment of liver fibrosis using T1 mapping on Gd-EOB-DTPA-enhanced magnetic resonance. Dig Liver Dis, 2017, 49(7): 789-795.
[16]
贾翠宇，赵大伟，许少华,等. MRI Gd-BOPTA增强肝胆期在肝细胞癌的诊断价值.临床放射学杂志, 2018, 37(11): 1865-1869.
[17]
殷亮，喻思思，龚良庚,等.心脏磁共振纵向弛豫时间定量成像技术进展.中华放射学杂志, 2016, 50(1): 76-78.
[18]
Atsukawa M, Tsubota A, Kato K, et al. Analysis of factors predicting the response to tolvaptan in patients with liver cirrhosis and hepatic edema. J Gastroenterol Hepatol, 2018, 33(6): 1256-1263.
[19]
Mehta KJ, Farnaud SJ, Sharp PA. Iron and liver fibrosis: Mechanistic and clinical aspects. World J Gastroenterol, 2019, 25(5): 521-538.
[20]
Hoad CL, Palaniyappan N, Kaye P, et al. A study of T(1) relaxation time as a measure of liver fibrosis and the influence of confounding histological factors. NMR Biomed, 2015, 28(6): 706-714.

PREV In vitro study of SR-A targeted multimodal nanoparticles for the detection of atherosclerotic vulnerable plaques
NEXT Evaluation the staging of rabbits’ liver fibrosis using diffusion kurtosis imaging: A pilot research
  


LINK


Tel & Fax: +8610-67113815    E-mail: editor@cjmri.cn